| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.34 | 0.09 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.092 | 0.09 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.083 | 0.1 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.1 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | BRD-K80183349 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |